Sanofi SA (SAN) PT Set at €74.00 by Jefferies Group
Sanofi SA (EPA:SAN) has been given a €74.00 ($82.22) target price by analysts at Jefferies Group in a research report issued on Thursday. The firm presently has a a “neutral” rating on the stock.
A number of other equities analysts have also weighed in on the company. JPMorgan Chase & Co. reaffirmed a “sell” rating on shares of Sanofi SA in a research report on Tuesday, October 4th. BNP Paribas set a €78.00 ($86.67) target price on Sanofi SA and gave the stock a “neutral” rating in a research report on Wednesday, September 14th. Berenberg Bank set a €93.00 ($103.33) target price on Sanofi SA and gave the stock a “buy” rating in a research report on Thursday, September 8th. Kepler Capital Markets set a €89.00 ($98.89) target price on Sanofi SA and gave the stock a “buy” rating in a research report on Thursday, August 11th. Finally, Societe Generale set a €100.00 ($111.11) target price on Sanofi SA and gave the stock a “buy” rating in a research report on Monday, August 1st. One investment analyst has rated the stock with a sell rating, nine have given a hold rating and seven have given a buy rating to the company. The stock presently has an average rating of “Hold” and an average price target of €86.65 ($96.27).
Sanofi SA (EPA:SAN) opened at 67.55 on Thursday. The company has a market capitalization of €86.94 billion and a PE ratio of 21.00. The firm’s 50-day moving average is €25.98 and its 200-day moving average is €25.76. Sanofi SA has a 52-week low of €22.81 and a 52-week high of €68.17.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at https://www.americanbankingnews.com/2016/10/13/sanofi-sa-san-pt-set-at-74-00-by-jefferies-group.html
Sanofi SA Company Profile
Sanofi, formerly Sanofi-Aventis, is a healthcare company engaged in the research, development, manufacture and marketing of therapeutic solutions. The Company operates through three segments: Pharmaceuticals, Human Vaccines (Vaccines) and Animal Health. The Pharmaceuticals segment consists of research, development, production and marketing of medicines, including those originating from Genzyme Corporation.
Receive News & Ratings for Sanofi SA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi SA and related companies with MarketBeat.com's FREE daily email newsletter.